Physician profile
Ashok Modh
NPI 1578592556
$14,418.71
in general payments reported to CMS, 2019-2025
42 companies · $3,802 in 2025
The $3,802 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,256 · 2020: $849 · 2021: $1,307 · 2022: $1,949 · 2023: $2,279 · 2024: $2,977 · 2025: $3,802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,863 · Consulting Fee: $150 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,863.20 |
| Consulting Fee | $150.00 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,821.76 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,581.69 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Harmony Biosciences LLC | $1,006.43 | 2020-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $957.76 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Jazz Pharmaceuticals INC. | $878.18 | 2019-2025 | Xywav |
| Takeda Pharmaceuticals U.S.A., INC. | $872.22 | 2020-2025 | Glassia |
| Genzyme Corporation | $820.19 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $711.40 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Insmed, INC. | $608.77 | 2019-2025 | Arikayce |
| United Therapeutics Corporation | $521.65 | 2021-2025 | Tyvaso, Orenitram, Tyvaso |
| Regeneron Healthcare Solutions, INC. | $436.43 | 2019-2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $417.92 | 2020-2025 | Acthar |
| Philips North America LLC | $284.15 | 2019-2025 | (Ae4) Secretion Management, Image Management Subscription, Vest Therapy Und |
| Merck Sharp & Dohme LLC | $260.74 | 2021-2025 | Winrevair |
| Amgen INC. | $249.72 | 2021-2025 | Tezspire, Tavneos |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $240.64 | 2021-2024 | |
| Ani Pharmaceuticals, INC. | $236.53 | 2024-2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $179.57 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Inspire Medical Systems, INC. | $162.10 | 2025 | Inspire |
| Mylan Specialty L.P. | $157.01 | 2019-2022 | |
| Advanced Respiratory, INC | $139.22 | 2019-2021 | |
| Verona Pharma, INC. | $100.46 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $90.96 | 2019-2021 | |
| Grifols USA, LLC | $84.10 | 2024 | Prolastin-C Liquid |
| Janssen Biotech, INC. | $75.89 | 2021 | |
| Genentech USA, INC. | $59.79 | 2019 | |
| Paratek Pharmaceuticals, INC. | $48.27 | 2019-2021 | |
| Resmed Corp | $45.54 | 2022-2023 | |
| Allergan, INC. | $43.39 | 2019 | |
| 3b Medical, INC. | $32.03 | 2023-2024 | Luna |
| Pulmonx Corporation | $30.75 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Teva Pharmaceuticals USA, INC. | $30.13 | 2022 | |
| Electromed, INC. | $29.60 | 2019 | |
| Shionogi INC | $29.15 | 2021-2023 | Fetroja |
| Bayer Healthcare Pharmaceuticals INC. | $28.83 | 2019 | |
| Abbvie INC. | $28.19 | 2023 | |
| Vapotherm INC | $26.79 | 2022 | |
| Covis Pharma Gmbh | $25.34 | 2022 | |
| Ambu INC. | $19.49 | 2023 | |
| Sanofi-Aventis U.S. LLC | $18.78 | 2019 | |
| Vanda Pharmaceuticals INC. | $13.71 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashok Modh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.